Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) - Pipeline Review, H2 2016

Published: Nov, 2016 | Pages: 85 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) - Pipeline Review, H2 2016', provides in depth analysis on Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) targeted pipeline therapeutics. 

The report provides comprehensive information on the Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: 
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) 
- The report reviews Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) 
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) Overview 9
Therapeutics Development 10
Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) - Products under Development by Stage of Development 10
Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) - Products under Development by Therapy Area 11
Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) - Products under Development by Indication 12
Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) - Pipeline Products Glance 14
Late Stage Products 14
Early Stage Products 15
Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) - Products under Development by Companies 16
Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) - Products under Development by Universities/Institutes 19
Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) - Therapeutics Assessment 21
Assessment by Monotherapy/Combination Products 21
Assessment by Mechanism of Action 22
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) - Companies Involved in Therapeutics Development 27
Akshaya Bio Inc. 27
Boehringer Ingelheim GmbH 28
Curevac AG 29
Etubics Corporation 30
GeoVax Labs Inc 31
Merck KGaA 32
Minerva Biotechnologies Corporation 33
Transgene SA 34
Vaxil Bio Therapeutics Ltd. 35
Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) - Drug Profiles 36
BI-1361849 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Cellular Immunotherapy to Target MUC1 for Gastric Cancer - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
CV-9104 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
GO-203/NPs - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
GO-2032c - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
ImMucin - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Monoclonal Antibody to Inhibit MUC1 for Oncology - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
tecemotide - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
TG-4010 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
Vaccine 1 to Target MUC-1 Protein for Breast Cancer - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
Vaccine 2 to Target MUC-1 for Breast Cancer - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
Vaccine 3 to Target MUC-1 Protein for Breast Cancer - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
Vaccine for Oncology - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
Vaccine for Oncology - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
Vaccine to Target MUC-1 and TLR-2 for Breast Cancer - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
Vaccine to Target MUC-1 for Cancer - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
Vaccine to Target MUC1 for Oncology - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
Vaccine to Target MUC1 for Oncology - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
Vaccine to Target MUC1 for Oncology - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
Vaccine to Target MUC1 for Oncology - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
Vaccine to Target MUC1 for Oncology - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
Vaccine to Target Mucin 1 for Oncology - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) - Dormant Projects 73
Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) - Discontinued Products 74
Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) - Featured News & Press Releases 75
Aug 04, 2016: Vaxil Announces Key US Patent and Trademark Office Notice of Allowance for Its Immunotherapy 75
Jun 16, 2016: Vaxil Receives Positive Response From European Patent Office for the Allowance of the Immunotherapy Orphan Drug Designated ImMucin 76
Apr 20, 2016: Studies published in "Oncogene" demonstrate that MUC1-C regulates DNA methylation in human carcinoma cells 78
Mar 31, 2016: Vaxil Receives Canadian Notice of Patent Allowance for Its Lead Immunotherapy Platform, Including Its ImMucin Cancer Vaccine 78
Mar 16, 2016: Genus Oncology completes enrollment to Phase 1b dose escalation study of GO-203 for the treatment of relapsed/refractory AML 79
Mar 09, 2016: Study in "Cancer Research" supports targeting MUC1-C to suppress MYC expression and attenuate lung cancer growth 79
Feb 17, 2016: Studies published in "Blood" demonstrate that MUC1-C drives MYC expression in multiple myeloma 79
Dec 23, 2015: Transgene Announces Publication in "The Lancet Oncology" of Phase 2b TIME Trial Results with TG4010 Immunotherapy in Non-Small Cell Lung Cancer 79
Nov 11, 2015: Genus receives orphan drug designation from the US FDA for GO-203 treatment of relapsed/refractory Acute Myeloid Leukemia 80
Sep 08, 2015: Transgene Announces Final Overall Survival Data from Phase 2b TIME Trial with TG4010 Immunotherapy in Non-Small Cell Lung Cancer 80
Aug 19, 2015: Transgene Announces Oral Presentation on TG4010 Cancer Immunotherapy at World Conference on Lung Cancer 81
Jun 22, 2015: Vaxil's Lead Product ImMucin has Been Granted an Orphan Drug Designation by the FDA for the Treatment of Multiple Myeloma 81
Jun 01, 2015: Transgene Announces Positive New Results Presented at ASCO from Phase 2b TIME Trial with TG4010 Immunotherapy in Non-Small Cell Lung Cancer 82
May 13, 2015: Preclinical results define approach for GO-203 administration in novel nanoparticles to target MUC1-C in human cancers 83
Apr 21, 2015: Transgene Presents New Pre-Clinical Data at AACR on the Combination of TG4010 with Immune Checkpoint Inhibitors 83
Appendix 84
Methodology 84
Coverage 84
Secondary Research 84
Primary Research 84
Expert Panel Validation 84
Contact Us 84
Disclaimer 85

List of Tables

Number of Products under Development for, H2 2016 10
Number of Products under Development by Therapy Area, H2 2016 11
Number of Products under Development by Indication, H2 2016 12
Comparative Analysis by Late Stage Development, H2 2016 14
Comparative Analysis by Early Stage Products, H2 2016 15
Number of Products under Development by Companies, H2 2016 16
Products under Development by Companies, H2 2016 17
Products under Development by Companies, H2 2016 (Contd..1) 18
Number of Products under Investigation by Universities/Institutes, H2 2016 19
Products under Investigation by Universities/Institutes, H2 2016 20
Assessment by Monotherapy/Combination Products, H2 2016 21
Number of Products by Stage and Mechanism of Action, H2 2016 22
Number of Products by Stage and Route of Administration, H2 2016 24
Number of Products by Stage and Molecule Type, H2 2016 26
Pipeline by Akshaya Bio Inc., H2 2016 27
Pipeline by Boehringer Ingelheim GmbH, H2 2016 28
Pipeline by Curevac AG, H2 2016 29
Pipeline by Etubics Corporation, H2 2016 30
Pipeline by GeoVax Labs Inc, H2 2016 31
Pipeline by Merck KGaA, H2 2016 32
Pipeline by Minerva Biotechnologies Corporation, H2 2016 33
Pipeline by Transgene SA, H2 2016 34
Pipeline by Vaxil Bio Therapeutics Ltd., H2 2016 35
Dormant Projects, H2 2016 73
Discontinued Products, H2 2016 74